The Korean Journal of Pain

The Korean Pain Society (대한통증학회)
권호 표지
DOI QR코드

DOI QR Code

An Open-Label Trial of the 5% Lidocaine Patches for the Treatment of Chronic Pain

다양한 만성 통증 질환에서 5% 리도카인 패치의 유용성 연구

  • Moon, Jee Youn (Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital) ;
  • Choi, Jong Bum (Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital) ;
  • Lee, Pyung Bok (Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital) ;
  • Son, He Min (Department of Anesthesiology and Pain Medicine, Seoul National University Hospital) ;
  • Nam, Francis Sanhgun (Department of Anesthesiology and Pain Medicine, Seoul National University Hospital) ;
  • Kim, Young Chul (Department of Anesthesiology and Pain Medicine, Seoul National University Hospital) ;
  • Lee, Sang Chul (Department of Anesthesiology and Pain Medicine, Seoul National University Hospital) ;
  • Lee, Sang Jin (Department of Anesthesiology and Pain Medicine, Kangwon National University Hospital)
  • 문지연 (분당서울대학교병원 마취통증의학과) ;
  • 최종범 (분당서울대학교병원 마취통증의학과) ;
  • 이평복 (분당서울대학교병원 마취통증의학과) ;
  • 손혜민 (서울대학교병원 마취통증의학과) ;
  • 남상건 (서울대학교병원 마취통증의학과) ;
  • 김용철 (서울대학교병원 마취통증의학과) ;
  • 이상철 (서울대학교병원 마취통증의학과) ;
  • 이상진 (강원대학교병원 마취통증의학과)
  • Received : 2009.07.06
  • Accepted : 2009.08.03
  • Published : 2009.12.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background: There have been limited reports on the effectiveness of 5% lidocaine patches (L5Ps) for treating a few types of chronic pain. We utilized L5Ps for chronic pain patients with various diagnoses and who had incompletely responded to their current treatment regimen. This study aimed at describing the results of a retrospective review of an open-label L5P trial to assess L5Ps' effectiveness and safety for treating various chronic pain patients. Methods: The chronic pain patients with pain lasting longer than 6-month duration were offered a 2-week L5P treatment trial. The patients were maintained on their other analgesic regimens. The treatment effect was measured according to the change from the baseline visual analog scale (VAS) to the week 2 VAS. After a 2-week trial, the patients were asked if they perceived pain improvement with L5Ps by using a four-item Pain Relief Scale (1 = a lot of relief, 2 = slight relief, 3 = no change, 4 = worse pain). Results: In the combined patient population (n = 177), 2-week treatment with the L5Ps significantly improved the week 2 VAS (P = 0.000). Significant improvement in the VAS was reported by the chronic pain patients with postherpetic neuralgia, intercostal neuralgia, degenerative osteoarthritis at knee joint, and other maladies. A higher proportion of the chronic pain patients reported improving their pain by the L5Ps. Seven patients experienced mild or moderate patch-related adverse events. Conclusions: The L5P provided clinically meaningful pain relief in some refractory chronic pain patients without any severe adverse events.

Keywords

References

  1. Verhaak PF, Kerssens JJ, Dekker J, Sorbi MJ, Bensing JM: Prevalence of chronic benign pain disorder among adults: a review of the literature. Pain 1998; 77: 231-9 https://doi.org/10.1016/S0304-3959(98)00117-1
  2. Mao J, Chen LL: Systemic lidocaine for neuropathic pain relief. Pain 2000; 87: 7-17 https://doi.org/10.1016/S0304-3959(00)00229-3
  3. Campbell BJ, Rowbotham M, Davies PS, Jacob P 3rd, Benowitz NL: Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. J Pharm Sci 2002; 91: 1343-50 https://doi.org/10.1002/jps.10133
  4. Davies PS, Galer BS: Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs 2004; 64: 937-47 https://doi.org/10.2165/00003495-200464090-00002
  5. Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M: Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analysis from an open-label, two-stage adaptive, randomized, controlled trial. Clin Drug Investig 2009; 29: 231-41 https://doi.org/10.2165/00044011-200929040-00002
  6. Zin CS, Nissen LM, Smith MT, O'Callaghan JP, Moore BJ: An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. CNS Drugs 2008; 22: 417-42 https://doi.org/10.2165/00023210-200822050-00005
  7. Barbano RL, Herrmann DN, Hart-Gouleau S, Pennella- Vaughan J, Lodewick PA, Dworkin RH: Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol 2004; 61: 914-8 https://doi.org/10.1001/archneur.61.6.914
  8. Argoff CE, Galer BS, Jensen MP, Oleka N, Gammaitoni AR: Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the neuropathic pain scale. Curr Med Res Opin 2004; 20(Suppl 2): 21-8 https://doi.org/10.1185/030079904X12960
  9. Hines R, Keaney D, Moskowitz MH, Prakken S: Use of lidocaine patch 5% for chronic low back pain: a report of four cases. Pain Med 2002; 3: 361-5 https://doi.org/10.1046/j.1526-4637.2002.02051.x
  10. Saber AA, Elgamal MH, Rao AJ, Itawi EA, Martinez RL: Early experience with lidocaine patch for postoperative pain control after laparoscopic ventral hernia repair. Int J Surg 2009; 7: 36-8 https://doi.org/10.1016/j.ijsu.2008.09.003
  11. Affaitati G, Fabrizio A, Savini A, Lerza R, Tafuri E, Costantini R, et al: A randomized, controlled study comparing a lidocaine patch, a placebo patch, and anesthetic injection for treatment of trigger points in patients with myofascial pain syndrome: evaluation of pain and somatic pain thresholds. Clin Ther 2009; 31: 705-20 https://doi.org/10.1016/j.clinthera.2009.04.006
  12. Kivitz A, Fairfax M, Sheldon EA, Xiang Q, Jones BA, Gammaitoni AR, et al: Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults. Clin Ther 2008; 30: 2366-77 https://doi.org/10.1016/j.clinthera.2008.12.015
  13. Sim WS, Choi JH, Han KR, Kim YC: Treatment of herpes zoster and postherpetic neuralgia. Korean J Pain 2008; 21: 93-105 https://doi.org/10.3344/kjp.2008.21.2.93
  14. Kim TH, Choi PT, Yoo JH, Kim KJ: A study on the effect of topical 5% lidocaine patches on postherpetic neuralgia. Annals of Dermatology 2007; 19: 1-8 https://doi.org/10.5021/ad.2007.19.1.1
  15. Gammaitoni AR, Alvarez NA, Galer BS: Pharmacokinetics and safety of continuously applied lidocaine patches 5%. Am J Health Syst Pharm 2002; 59: 2215-20
  16. Devers A, Galer BS: Topical lidocaine patch relieves a variety of neuropathic pain conditions: an open-label study. Clin J Pain 2000; 16: 205-8 https://doi.org/10.1097/00002508-200009000-00005
  17. Fishbain DA, Lewis JE, Cole B, Cutler B, Rosomoff HL, Rosomoff RS: Lidocaine 5% patch: an open-label naturalistic chronic pain treatment trial and prediction of response. Pain Med 2006; 7: 135-42 https://doi.org/10.1111/j.1526-4637.2006.00108.x
  18. Gimbel J, Linn R, Hale M, Nicholson B: Lidocaine patch treatment in patients with low back pain: results of an open-label, nonrandomized pilot study. Am J Ther 2005; 12: 311-9 https://doi.org/10.1097/01.mjt.0000164828.57392.ba
  19. Galer BS, Gammaitoni AR, Oleka N, Jensen MP, Argoff CE: Use of the lidocaine patch 5% in reducing intensity of various pain qualities reported by patients with low-back pain. Curr Med Res Opin 2004; 20(Suppl 2): 5-12 https://doi.org/10.1185/030079903125002667
  20. Zhang JM, Li H, Munir MA: Decreasing sympathetic sprouting in pathologic sensory ganglia: a new mechanism for treating neuropathic pain using lidocaine. Pain 2004; 109: 143-9 https://doi.org/10.1016/j.pain.2004.01.033
  21. Galer BS, Sheldon E, Patel N, Codding C, Burch F, Gammaitoni AR: Topical lidocaine patch 5% may target a novel underlying pain mechanism in osteoarthritis. Curr Med Res Opin 2004; 20: 1455-8 https://doi.org/10.1185/030079904X2754
  22. White WT, Patel N, Drass M, Nalamachu S: Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. Pain Med 2003; 4: 321-30 https://doi.org/10.1111/j.1526-4637.2003.03045.x
  23. Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M: Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in postherpetic neuralgia and diabetic polyneuropathy. Curr Med Res Opin 2009; 25: 1677-87 https://doi.org/10.1185/03007990903048078
  24. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al: Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007; 132: 237-51 https://doi.org/10.1016/j.pain.2007.08.033
  25. Finnerup NB, Otto M, Jensen TS, Sindrup SH: An evidence- based algorithm for the treatment of neuropathic pain. MedGenMed 2007; 9: 36

Cited by

  1. Use of Lidocaine Patch for Percutaneous Endoscopic Lumbar Discectomy vol.24, pp.2, 2011, https://doi.org/10.3344/kjp.2011.24.2.74
  2. Effect of Fentanyl Nasal Packing Treatment on Patients With Acute Postoperative Pain After Nasal Operation: A Randomized Double-Blind Controlled Trial vol.127, pp.5, 2018, https://doi.org/10.1177/0003489418759113